Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
₹ 216.1
Key Takeaways
Risk factor
Very poor trading liquidity
Data is available to registered users only
Data is available to registered users only
Profitability factor
Undervalued vs peers
Data is available to registered users only
Data is available to registered users only
About
Samrat Pharmachem Ltd. engages in the manufacturing manufacturing and selling chemicals. Its products include 3-5–Di iodosalicylic acid, aluminium iodide, clioquinol, ethylenediamine dihydroiodide, copper iodine, and lithium iodide. The company was founded by Lalit Damodar Mehta on June 16, 1992, and is headquartered in Mumbai, India.
Company Valuation
Based on key historical and expected multiples, the stock is undervalued relative to its peers. In particular, the stock is reasonably priced on P/E, of fair value on EV/
Data is available to registered users only
Buy
Sell